Biogen Inc. investors can advance their claim that the company misrepresented clinical trial data for its Alzheimer’s drug, a federal judge ruled.
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback